(EMAILWIRE.COM, January 31, 2019 ) The research report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global viral inactivation market along with the estimates and forecasts of the revenue and market share analysis.

Don’t miss out on business opportunities in viral inactivation market.

Viral inactivation testing is necessary by regulatory authorities for investigational new drug (IND) submission and is mainly critical in process development for biologicals including tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, and vaccine and therapeutics. The major drivers for the market are rapid growth in pharmaceutical and biotechnology industries and strong trend of R&D investments in the life sciences industry.

Download PDF Brochure (Viral Inactivation):

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121427017

The Global viral inactivation market is segmented based on method, product, application, end user, and geography. The method segments included in the report are the solvent detergent method, pasteurization, and other methods.

Global Viral Inactivation Market by Application;

- Blood & Blood Products
- Cellular & Gene Therapy Products
- Stem Cell Products
- Tissue & Tissue Products
- Vaccines and Therapeutics

Viral inactivation is an important and mandatory step in the manufacturing process of biological products to remove or inactivate potential contaminant viruses. These biological products are used for the treatment and diagnostic purposes in humans. As the disease burden in the world is increasing the demand for the medicines is increasing hence the production of biologicals, injectables etc. are on a rise. Also, many pharmaceutical and biotechnology firms are gearing to cater to the growing demands of medicines.

Speak To Analyst (viral inactivation market):

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=121427017

Major players in the viral inactivation market:

Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).